The Academy is responding to the House of Commons Science and Technology Committee's inquiry into clinical trials and disclosure of data.
The inquiry includes questions about the proposed European Clinical Trials Regulation; the role of the new Health Research Authority (HRA); and the debate about the transparency of clinical trial data.
The response will be available online once the House of Commons has published the evidence.
The President's thoughts have been compiled and sent to the Fellowship to inform them of the situation, and they are available to download from this page.